Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allegion PLC (ALLE) vs Eli Lilly And Co (LLY) Price & Performance

Allegion PLCTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Allegion PLC vs Eli Lilly And Co — how do they compare? Allegion PLC trades at $166.45 (market cap $14.32B), while Eli Lilly And Co trades at $1,220.21 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 75.4× Allegion PLC's market cap, and Allegion PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.

ALLELLY
Market Cap
$14.32B$1.08T
Sector
IndustrialsHealth
52-Week High
$179.77$1.24K
52-Week Low
$125.65$639.43
Enterprise Value
$16.03B$1.13T
Dividend Yield
1.26%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allegion PLC

ALLE trades at $165.9, up 0.22% today, near its consensus price target of $156. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates, driven by 13% revenue growth and margin expansion in the Americas segment. Recent news highlights raised full-year guidance and institutional buying interest.

Outlook remains positive given earnings momentum and raised guidance, but risks include reliance on Americas growth and cost pressures. Analyst sentiment is mixed with a Hold consensus, yet the stock's current price above the target suggests limited near-term upside. Execution on international growth and margin sustainability are key for further appreciation.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allegion PLC

Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.

Read more on ALLE

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY